

# PD-1 and PD-L1 inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/PAF26F1A7927EN.html>

Date: January 2022

Pages: 200

Price: US\$ 2,500.00 (Single User License)

ID: PAF26F1A7927EN

## Abstracts

This report can be delivered to the clients within 2-3 Business Days

DelveInsight's, "PD-1 and PD-L1 inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in PD-1 and PD-L1 inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### PD-1 and PD-L1 inhibitors Understanding

#### PD-1 and PD-L1 inhibitors: Overview

PD-1 and PD-L1/PD-L2 belong to the family of immune checkpoint proteins that act as co-inhibitory factors that can limit the development of the T cell response. The PD-1 (programmed cell death-1) receptor is expressed on the surface of activated T cells. Its ligands, PD-L1 and PD-L2, are expressed on the surface of dendritic cells or macrophages. The PD-1/PD-L1 interaction ensures that the immune system is activated only at the appropriate time in order to minimize the possibility of chronic autoimmune inflammation. The PD-1/PD-L1 pathway represents an adaptive immune resistance mechanism exerted by tumor cells in response to endogenous immune anti-tumor activity. PD-L1 is overexpressed on tumor cells or on non-transformed cells in the tumor microenvironment. PD-L1 expressed on the tumor cells binds to PD-1 receptors on the

activated T cells, which leads to the inhibition of the cytotoxic T cells. Monoclonal antibodies specific to the PD-1 and PD-L1 immune checkpoints have been approved for the treatment of various tumors. PD-1/PD-L1 inhibitors may be combined with other immunotherapies or traditional treatments to enhance efficacy relative to that using PD-1/PD-L1 therapy alone.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence PD-1 and PD-L1 inhibitors R&D. The therapies under development are focused on novel approaches for PD-1 and PD-L1 inhibitors.

## PD-1 and PD-L1 inhibitors Emerging Drugs Chapters

This segment of the PD-1 and PD-L1 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## PD-1 and PD-L1 inhibitors Emerging Drugs

### Tislelizumab: BeiGene

Tislelizumab (BGB-A317) is a humanized IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to Fc $\gamma$ R on macrophages. Tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers. Tislelizumab was designed to bind to PD-1, a cell surface receptor that plays an important role in allowing tumor cells to evade the immune system. Tislelizumab was first approved in China in late 2019 as a third-line treatment for classical Hodgkin lymphoma. In January 2021, Novartis signed a collaboration agreement to in-license tislelizumab from BeiGene in major markets outside of China.

### Dostarlimab: GlaxoSmithKline

Dostarlimab is a humanized PD-1 monoclonal antibody that binds with high affinity to the PD-1 receptor and blocks its interaction with the ligands PD-L1 and PD-L2. Dostarlimab is being investigated in recurrent or primary advanced endometrial cancer in combination with standard of care (SOC) chemotherapy and for stage III or IV non-mucinous epithelial ovarian cancer. It is also being evaluated in combination with other therapeutic agents for patients with advanced solid tumors or metastatic cancer. Dostarlimab was discovered by AnaptysBio and licensed to TESARO under a Collaboration and Exclusive License Agreement signed in March 2014.

Further product details are provided in the report.....

## PD-1 and PD-L1 inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different PD-1 and PD-L1 inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

### Major Players working on PD-1 and PD-L1 inhibitors

There are approx. 70+ key companies which are developing the PD-1 and PD-L1 inhibitors. The companies which have their PD-1 and PD-L1 inhibitors drug candidates in the most advanced stage, i.e. Registration include, GlaxoSmithKline.

### Phases

DelveInsight's report covers around 70+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

## Route of Administration

PD-1 and PD-L1 inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

PD-1 and PD-L1 inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses PD-1 and PD-L1 inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging PD-1 and PD-L1 inhibitors drugs.

PD-1 and PD-L1 inhibitors Report Insights

PD-1 and PD-L1 inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

PD-1 and PD-L1 inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

## Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing PD-1 and PD-L1 inhibitors drugs?

How many PD-1 and PD-L1 inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for PD-1 and PD-L1 inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the PD-1 and PD-L1 inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for PD-1 and PD-L1 inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

BeiGene

GlaxoSmithKline

Shanghai Junshi Biosciences

Merck & Co

Innovent Biologics

Phio Pharmaceuticals

Curocell

Oneness Biotech

Seneca Therapeutics

Lyvgen Biopharma

Jiangsu Hengrui Medicine

Curis

Sinocelltech

Taizhou HoudeAoke Biomedical

Y-Biologics

Merck KGaA

Celgene

MedImmune

Genentech

## Key Products

Tislelizumab

Dostarlimab

Toripalimab

Pembrolizumab

IBI-318

PH 762-TME

CRC-01

SNA-01

SVV-012

Research programme: bispecific antibodies

Camrelizumab

Carrizumab

CA-170

SNA-02

SCT-B07

LP 002

YBL-027

Avelumab

Durvalumab

Atezolizumab



## Contents

Introduction

Executive Summary

PD-1 and PD-L1 inhibitors: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

PD-1 and PD-L1 inhibitors – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

PD-1 and PD-L1 inhibitors companies' collaborations, Licensing, Acquisition -Deal Value Trends

PD-1 and PD-L1 inhibitors Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Registration)

Comparative Analysis

Dostarlimab: GlaxoSmithKline

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Tislelizumab: BeiGene

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

PH 762-TME: Phio Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

PD-1 and PD-L1 inhibitors Key Companies

PD-1 and PD-L1 inhibitors Key Products

PD-1 and PD-L1 inhibitors- Unmet Needs

PD-1 and PD-L1 inhibitors- Market Drivers and Barriers

PD-1 and PD-L1 inhibitors- Future Perspectives and Conclusion

PD-1 and PD-L1 inhibitors Analyst Views

PD-1 and PD-L1 inhibitors Key Companies

Appendix

## List Of Tables

### LIST OF TABLES

Table 1 Total Products for PD-1 and PD-L1 inhibitors

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

- Figure 1 Total Products for PD-1 and PD-L1 inhibitors
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

## I would like to order

Product name: PD-1 and PD-L1 inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/PAF26F1A7927EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PAF26F1A7927EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970